MIRM insider trading
HealthcareMirum Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Company website: www.mirumpharma.com
MIRM insider activity at a glance
FilingIQ has scored 408 insider transactions for MIRM since Jul 22, 2019. The most recent filing in our index is dated Apr 15, 2026.
Across the full history, 64 open-market purchases
and 111 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MIRM insider trades is 61.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MIRM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding MIRM
Frequently asked
- How many insider trades does FilingIQ track for MIRM?
- FilingIQ tracks 408 Form 4 insider transactions for MIRM (Mirum Pharmaceuticals, Inc.), covering filings from Jul 22, 2019 onwards. 29 of those were filed in the last 90 days.
- Are MIRM insiders net buyers or net sellers?
- Across the full Form 4 history for MIRM, 64 transactions (16%) were open-market purchases and 111 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MIRM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MIRM in?
- Mirum Pharmaceuticals, Inc. (MIRM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.08B.
Methodology & sources
Every MIRM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.